Scott Adams, the creator of the "Dilbert" comics, has died less than eight months after he announced he had been diagnosed with prostate cancer. The 68-year-old's death was announced by his ex-wife, Shelly Miles, during Tuesday’s livestream of Adams's daily show, “Coffee with Scott Adams."

Probiotics and broccoli could help to slow the spread of prostate cancer, research suggests. Broccoli, turmeric, pomegranate, green tea, ginger and cranberry were combined in a supplement and given to men whose prostate cancer was classed as low-risk.

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving therapy.

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product candidate, Enolen, to expedite the development of a localized treatment for patients with low to intermediate risk prostate cancer.

I get stopped regularly from people asking me where do things stand with my prostate cancer treatment. I'm following through on my journey--which began just over two years ago with my diagnosis.

A research team at the University of Würzburg has, for the first time, uncovered how E. coli bacteria sneak into the prostate. The study opens the door to potential new treatments for bacterial prostatitis.

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment. Initial diagnosis and treatment left the author feeling weak and unsupported, highlighting a lack of guidance on lifestyle adjustments.

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance A032304) to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.

The novel MEK inhibitor atebimetinib in combination with modified gemcitabine/nab-paclitaxel led to a 12-month overall survival rate of 64% among first-line pancreatic cancer patients in an ongoing phase IIa trial, Immuneering announced.